Outcome research in gastroenterology: The case of gastroesophageal reflux disease (GERD)

Drug Development Research

Volumn 67, Issue 3, 2006, Pages 251-259

  Pace, Fabio ^a   Molteni, Paola ^a   Wiklund, Ingela ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

GERD; H2 RA; Health related quality of life (HRQoL); PPI

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ANXIETY; ARTHRITIS; BACKACHE; BARRETT ESOPHAGUS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; EPIGASTRIC PAIN; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HUMAN; OUTCOMES RESEARCH; QUALITY OF LIFE; REFLUX ESOPHAGITIS; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SLEEP DISORDER; TREATMENT OUTCOME;

EID: 33746256072     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20083     Document Type: Review

References (51)

1. Beers MH, Berkov R, editors. 1999. Gastrointestinal disorders: the Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories.
2. Burton WN, Morrison A, Wertheimer AI. 2003. Pharmaceuticals and worker productivity loss: a critical review of the literature. J Occup Environ Med 45:610-621.
3. Carlsson R, Dent J, Watts R, et al. 1998. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 10:119-124.
4. Coyne KS, Wiklund I, Schmier J, Hailing K, Degli Innocenti A, Revicki D. 2003. Development and validation of a disease-specific treatment satisfaction questionnaire for gastro-oesophageal reflux disease, Aliment Pharmacol Ther 18:907-915.
5. Dean BB, Crawley JA, Reeves JD, Aguilar D, Sullivan S, Berglund R, Dubois R. 2003a. The cost of gastroesophageal reflux disease: It's what you don't see that counts. J Managed Care Med 7: 6-713.
6. Dean BB, Aguilar D, Crawley JA, Dubois R. 2003b. Impact of gastroesophageal reflux disease on worker productivity in an employed US population. Gastroenterology 124(suppl. 1):A-505 (poster presentation).
7. Dean BB, Crawley JA, Schmitt CM, Wong J, Ofman JJ. 2003c. The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 17:1309-1317.
8. Dent J, Brun J, Fendrick AM, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw M, Talley NJ, on behalf of the Genval Workshop Group. 1999. An evidence-based appraisal of reflux disease management: The Genval Workshop Report. Gut 44(Suppl 2):S1-S16.
9. DeVault KR, Castell DO. 1999. Updated guidelines for the diagnosis and treatment of gastroeso-phageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 94:1434-1442.
10. Engels LGJB, Klinkenberg-Knol EC, Dekkers CPM, Beker JA, Tan TG, Timmerman RJ, Haeck PWE. 2003. Esomeprazole continues versus on demand maintenance therapy in 1052 gastro-esophageal reflux disease patients: similar satisfaction but superior quality of life for once daily treatment (abstract). Gut 52:A130.
11. Epstein AM. 1990. The outcomes movement-will it get us where we want to go? N Engl J Med 266-270.
12. Epstein RS, Sherwood LM. 1996. From outcomes research to disease management. A guide for the perplexed. Ann Intern Med 124:832-837.
13. Eslick GD, Jones MP, Talley NJ. 2003. Non-cardiac chest pain: prevalence, risk factors, impact and consulting: a population-based study. Aliment Pharmacol Ther 17:1115-1124.
14. Farup C, Kleinman L, Slon S, Ganoczy D, Chee E, Ue C, Revicki D. 2001. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 161:45-52.
15. Gallup Survey on Heartburn across America. 1998. Princeton: Gallup Organization.
16. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. 2000. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119:654-660.
17. Havelund T, Lind T, Wiklund I, Glise H, Hernquist H, Lauritsen K, Lundell L, Pederson SA, Carlsson R, Junghard O, Stubberod A, Anker-Hansen O. 1999. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 94:1783-1790.
18. Holmes WF, MacGregor EA, Sawyer JP, Lipton RB. 2001. Information about migraine disability influences physicians' perceptions of illness severity and treatment needs. Headache 41: 343-350.
19. Isolauri J, Laippala P. 1995. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med 27:67-70.
20. Kaplan-Machlis B, Spiegler G, Zodet MW, Revicki DA. 2000. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophagem reflux disease in primary care clinics in West Virginia. Arch Fam Med 9:624-630.
21. Karlson BW, Wiklund I, Bengtson A, Herlitz J. 1994. Prognosis, severity of symptoms, and aspects of well-being among patients in whom myocardial infarction was ruled out. Clin Cardiol 17: 427-431.
22. Kartman B, Gatz G, Johannesson M. 2001. Health state utilities in GERD patients with heartburn: a study in Germany and Sweden. Value Health 4:512.
23. Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolte M, Willich SN. 2003. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease: an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 18:767-776.
24. Little P, Dorward M, Warner G, Moore M, Stephens K, Senior J, Kendrick T. 2004. Randomised controlled trial of effect of leaflets to empower patients in consultations in primary care. BMJ 328:441.
25. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. 1997. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olrnsted County, Minnesota. Gastroenterology 12:1448-1456.
26. Madisch A, Kulich KR, Malfertheiner P, Ziegler K, Bayerdorffer E, Miehlke S, Labenz J, Carlsson J, Wiklund IK. 2003. Impact of reflux disease on general and disease-related quality of life: evidence from a recent comparative methodological study in Germany. Z Gastroenterol 41:1137-1143.
27. National Heartburn Alliance: Survey 2000 Results: A Community Perspective, www. heartburnalliance.org/survey2000.pdf
28. Outcomes of Cancer Outcomes Research. 2002. Focusing on the National Cancer Institute's Quality of Care Initiative. Med Care 40:3-10.
29. Oster G, Tompson D, Kaatz S, Andersen K, Cavanaugh R, Crawley J, Johnson K, Schreiber D, Weinberg R, Guilbert D. 1998. The GORD outcomes trial: a randomized study to assess outcomes and cost in primary care practice. Gastmenterology 114:A32 (abst).
30. Pace F, Negrini C, Wiklund I, Rossi C, Savarino V, On Behalf Of The Italian One Investigators Study Group. 2005. Quality of life in acute and maintenance treatment of non-erosive gastro-oesophageal disease. Results from the ONE study. Aliment Pharmacol Ther 15:349-356.
31. Peterson WL. 2002. Improving the management of GERD: evidence-based therapeutic strategies. Bethesda, MD: American Gastroenterological Association.
32. Prasad M, Rentz AM, Revicki DA. 2003. The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life. A literature review. Pharmacoeconomics 21: 769-790.
33. Revicki DA, Sorensen S, Maton P, Orlando PC. 1998a. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesopbageal reflux disease. Dig Dis 16:284-291.
34. Revicki DA, Wood M, Maton PN, Sorensen S. 1998b. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 104:252-258.
35. Revicki DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO. 1999. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 13:1621-1630.
36. Rush DR, Stelmach WJ, Young TL, Kirchdoerfer LJ, Scott-Lenox J, Holverson HE, Sabesin SM, Nicholas TA. 1995. Clinical effectiveness and quality of life with ranitidine vs. placebo in gastro-esophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract 41:126-136.
37. Shaker R, Casteli DO, Schoenfeld PS, Spechler SJ. 2003. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 98:1487-1493.
38. Sjoland H, Wiklund I, Caidahl K, Haglid M, Westberg S, Herlitz J. 1996. Improvement in quality of life and exercise capacity after coronary bypass surgery. Arch Intern Med 156:265-271.
39. Stanghellini V, Armstrong A, Monnikes H, Bardhan DK. 2004. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther 19:463-479.
40. Stewart AL, Hays RD, Ware JE Jr. 1988. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 26:724-735.
41. Stewart MA. 1995. Effective physician-patient communication and health outcomes: A review. CMAJ 152:1423-1433.
42. Talley NJ, Junghard O, Wikiund IK. 2001. Why do patients with gastroesophageal reflux disease (GERD) have a poor heath-related quality of life (HRQL)? (Abstract). Gastroenterology 120:A423.
43. Trus TL, Laycock WS, Waring JP, Branum GD, Hunter JG. 1999. Improvement in quality of life measures after laparoscopic antireflux surgery. Ann Surg 229:331-336.
44. Wahlqvist P, Carlsson J, Stalbammar NO, Wiklund I. 2002. Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD): results from a cross-sectional study. Value Health 5: 106-113.
45. Ware JE, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier J, Bullinger M, Kaas S, Leplege A, Prieto L, Sullivan M, Thunedborg K. 1998. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: Results from the IQOLA Project. International Qual of Life Assessment. J Clin Epidemiol 51:1167-1170.
46. Watson RGP, Tham TCK, Johnston BT, McDougall NI. 1997. Double-blind cross-over placebo-controlled study of omeprazole in the treatment of patients with reflux Symptoms and physiological levels of acid reflux: the "sensitive oesophagus". Gut 40: 587-590.
47. Wiklund I. 2001. Quality of life in patients with gastroesophageal reflux disease. Am J Gastroenterol 96:S46-S53.
48. Wiklund I, Talley N. 2003. Update on health-related quality of life in patients with gastroesophageal reflux disease. Expert Rev Pharmacoeconomics Outcomes Res 3:341-350.
49. Wiklund I, Bardhan KD, Muller-Lissner S, et al. 1998. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine: results from a multicentre clinical trial. Ital J Gastroenterol Hepatol 30: 19-27.
50. Wiklund I, Hansen A, Bergheim R, Mourn B. 2003. Esomeprazole is superior to ranitidine 150 mg bid in maintaining quality of life (QoL) in patients with symptomatic GERD. Scand J Gastroenterol 38:22.
51. Youngs MT, Wingerson L. 1995. The 1996 medical outcomes & guidelines sourcebook. New York: Faulkner & Gray.